Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Soleno Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PHILADELPHIA, PENNSYLVANIA--(NEWSFILE CORP. - MARCH 13, 2026) - GRABAR LAW OFFICE IS INVESTIGATING CLAIMS ON BEHALF OF SHAREHOLDERS OF SOLENO THERAPEUTICS, INC. ("SOLENO" OR THE "COMPANY") (NASDAQ: SLNO). THE INVESTIGATION CONCERNS WHETHER SOLENO AND CERTAIN OF ITS EXECUTIVES VIOLATED THE FEDERAL SECURITIES LAWS BY MAKING MATERIALLY FALSE AND MISLEADING STATEMENTS AND FAILING TO DISCLOSE ADVERSE INFORMATION ABOUT THE SAFETY PROFILE AND COMMERCIAL PROSPECTS OF ITS DRUG CANDIDATE DCCR (DIAZOXIDE CHOLINE EXTENDED-RELEASE TABLETS), MARKETED AS VYKAT XR.

NOTICE TO LONG-TERM INVESTORS OF SOLENO THERAPEUTICS, INC. (SLNO): GRABAR LAW OFFICE INVESTIGATES CLAIMS ON YOUR BEHALF

LOS ANGELES, MARCH 12, 2026 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SOLENO THERAPEUTICS, INC. ("SOLENO" OR "THE COMPANY") (NASDAQ: SLNO) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SLNO DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

SOLENO THERAPEUTICS, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS - SLNO

LOS ANGELES--(BUSINESS WIRE)--SOLENO THERAPEUTICS, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  SLNO.

SOLENO THERAPEUTICS, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  SLNO

NEW YORK--(BUSINESS WIRE)--ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES A CLASS ACTION LAWSUIT ON BEHALF OF PURCHASERS OF COMMON STOCK OF SOLENO THERAPEUTICS, INC. (NASDAQ: SLNO) BETWEEN MARCH 26, 2025 THROUGH NOVEMBER 4, 2025. SOLENO DESCRIBES ITSELF AS A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL THERAPEUTICS FOR THE TREATMENT OF RARE DISEASES. FOR MORE INFORMATION, SUBMIT A FORM, EMAIL ATTORNEY PHILLIP KIM, OR GIVE US A CALL AT 866-767-3653. THE ALLEGATIONS: ROSE.

ROSEN LAW FIRM URGES SOLENO THERAPEUTICS, INC. (NASDAQ: SLNO) STOCKHOLDERS TO CONTACT THE FIRM FOR INFORMATION ABOUT THEIR RIGHTS

REDWOOD CITY, CALIF., FEB. 25, 2026 (GLOBE NEWSWIRE) -- SOLENO THERAPEUTICS, INC. (SOLENO) (NASDAQ: SLNO), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR THE TREATMENT OF RARE DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR ENDED DECEMBER 31, 2025 AND PROVIDED AN UPDATE ON THE U.S. LAUNCH OF VYKATXR (DIAZOXIDE CHOLINE) EXTENDED-RELEASE TABLETS.

SOLENO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS AND PROVIDES UPDATE ON U.S. LAUNCH OF VYKAT XR

NEW YORK, JAN. 8, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SOLENO THERAPEUTICS, INC. ("SOLENO" OR THE "COMPANY") (NASDAQ: SLNO).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF SOLENO THERAPEUTICS, INC. - SLNO

NEW YORK, JAN. 06, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SOLENO THERAPEUTICS, INC. (SOLENO OR THE COMPANY) (NASDAQ: SLNO). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

REDWOOD CITY, CALIF., JAN. 05, 2026 (GLOBE NEWSWIRE) -- SOLENO THERAPEUTICS, INC. (SOLENO) (NASDAQ: SLNO), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR THE TREATMENT OF RARE DISEASES, TODAY ANNOUNCED A PUBLICATION IN THE PEER-REVIEWEDJOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM (JCEM). THE PAPER, TITLED, DIAZOXIDE CHOLINE EXTENDED-RELEASE TABLETS IN PRADER-WILLI SYNDROME: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, WITHDRAWAL PERIOD STUDY, DETAILS RESULTS FROM THE 16-WEEK RANDOMIZED WITHDRAWAL STUDY (C602-RWP) OF VYKAT XR (ALSO KNOWN AS DIAZOXIDE CHOLINE EXTENDED-RELEASE TABLETS, OR DCCR) IN CHILDREN AND ADULTS 4 YEARS AND OLDER WITH HYPERPHAGIA IN PRADER-WILLI SYNDROME (PWS). THE PAPER CAN BE ACCESSED ONLINE HERE .

SOLENO THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM PIVOTAL STUDY OF VYKAT XR IN THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM

NEW YORK, JAN. 1, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SOLENO THERAPEUTICS, INC. ("SOLENO" OR THE "COMPANY") (NASDAQ: SLNO).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK , DEC. 11, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SOLENO THERAPEUTICS, INC. ("SOLENO" OR THE "COMPANY") (NASDAQ: SLNO). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLEPEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

Soleno Therapeutics, Inc.

SLNO

Price

Financial Reports

No items found.

Press Releases

Soleno Therapeutics, Inc.

SLNO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

SLNO